Saturday, February 5, 2011
Cytomegalovirus Tied to Hearing Loss in Kids
Cytomegalovirus (CMV), a common virus that usually does not make most people sick, may be associated with hearing loss in kids if mom is infected while pregnant according to a new study. In this study, 354 kids who were 4 years of age and up who had been tested for CMV and had hearing loss were examined. Thirty-four contracted CMV from their mothers and it was observed that kids who were CMV-positive at birth had more severe hearing loss than kids who were not and were more likely to have hearing loss in only one ear. Researchers did not have any clear answers as to why contracting CMV in utero may cause hearing problems. CMV is known to cause serious problems in babies if the mother contracts it during pregnancy. The next step will be to investigate how CMV causes hearing loss.
Thursday, October 21, 2010
CMV Poses Great Risk to Babies
More children have disabilities due to congenital CMV (cytomegalovirus) than other well-known infections and syndromes including Down Syndrome, Fetal Alcohol Syndrome, Spina Bifida and Pediatric HIV/AIDS. In a recent survey of women in the United States, only 22 percent had heard of CMV, compared with 97 percent who had heard of Down Syndrome and 98 percent who had heard of HIV/AIDS.
According to the Centers for Disease Control and Prevention, CMV is the most common congenital (present at birth) viral infection in the United States. One in 150 children is born infected with congenital CMV. Each year, 30,000 children are born with congenital CMV causing 400 deaths and leaving 8,000 children with permanent disabilities such as deafness, blindness, cerebral palsy, mental and physical disabilities and seizures.
In the United States, about 50 percent to 60 percent of women are at risk for contracting CMV infection during pregnancy. The American College of Obstetricians and Gynecologists and the CDC recommend that OB/GYNs counsel women on basic prevention measures to guard against CMV infection. But according to a 2007 survey, only 44 percent of OB/GYNs reported counseling their patients about preventing CMV. This could be due to the perceived rarity of congenital CMV cases, the OB/GYN's possible limited knowledge of the virus, the lack of congenital CMV diagnoses within their practice or just a simple oversight.
CMV is a very common virus in young children and it is estimated that up to 70 percent of healthy children between the ages of 1 and 3 may have CMV. CMV can be transmitted to pregnant women via bodily fluids including saliva, urine, tears, blood or mucus. To prevent CMV, practice frequent handwashing with soap and water after contact with diapers or oral secretions, especially with a child who is in daycare or interacting with other young children on a regular basis. Other basic prevention measures to guard against CMV include not kissing young children on the mouth and not sharing food, towels or utensils with them.
Stop CMV understands how difficult it may be to adjust one's daily routine while pregnant, especially for mothers and those women who work as child care providers, daycare workers, nurses, teachers and therapists.
However, it is important for these messages to be communicated to pregnant women and those planning future pregnancies in order to inform and empower them to take a more active role in their personal hygiene and health care decisions.
Karen Gillis
Anchorage
Representative for Alaska for Stop CMV
Tuesday, October 5, 2010
New Discovery Targets Cytomegalovirus (CMV)
To determine the effectiveness of a drug, NIAID uses a Selectivity Index (SI) as criteria to determine the potency of a drug. The SI measures CC50 (amount of drug required to kill 50% of uninfected cells) and EC50 (amount of drug needed to cause 50% inhibition of viral replication). CC50 divided by EC50=SI. The in vitro results, which were performed in cell culture and in plaque reduction assay (the gold standard) showed significant and potent antiviral effect in a head- to- head comparison against Ganciclovir, which is marketed by Roche and generated revenues of $546 million in 2008. (For test results click the following link) http://www.tamirbio.com/Comparing_Onconase_and_P31_to_Ganciclovir_against_Human_Cytomegalovirus.html
Within the last several months, we have reported significant results for our compounds against Dengue Fever, Yellow Fever, SARS, and now CMV. We are on the cusp of building an impressive drug portfolio that will be targeting viruses where there is currently an unmet need. Besides the fact that our drugs have shown significant antiviral activity against the viruses mentioned above, equally impressive is the fact that very low concentrations of our drugs were needed in order to show this significant antiviral activity.
In the case of CMV, where toxicity is of primary concern for current approved drugs, this has not been the case in the studies performed with our drugs. Moreover, Onconase®, our lead candidate, has been in clinical studies for other indications and has proven to be well tolerated in over 1,000 patients treated to date. NIAID will now be conducting animal studies for Dengue Fever, Yellow Fever, SARS, and CMV. Our goal is to enter into clinical trials for these viruses in the near future. "These are very exciting times for our shareholders, primary care physicians, and for those patients suffering from these diseases who for so long, have been waiting for drugs that are safe and effective," stated Tamir Chief Executive Officer Charles Muniz.
About Cytomegalovirus (CMV)
CMV is a member of the herpesvirus family. This family of viruses also causes chicken pox, shingles, mononucleosis (mono), genital herpes, and cold sores. In the United States, between 50% and 85% of the population will become infected with CMV by the time they reach age forty. Once a person is infected, the virus will remain alive, but dormant in their body for life. In most cases, CMV does not cause disease. However, CMV can cause severe and occasionally life-threatening disease in people with weakened immune systems.
Who's at Risk
Patients with weakened immune systems and patients receiving drugs to suppress their immune system, such as:
- Solid Organ Transplant Recipients
- Bone Marrow Transplant Recipients
- Cancer Patients
- Patients with HIV/AIDS (CMV Retinitis)
- Babies Infected With CMV Before Birth (Congenital CMV)
How Is CMV Spread
CMV is spread from person to person through close contact with body fluids, such as urine, blood, saliva, semen, vaginal fluids, and breast milk.
Signs and Symptoms
Active infection can cause prolonged high fever, pneumonia, blindness, diarrhea, liver infection, kidney damage, chills, fatigue, headache, enlarged spleen, and encephalitis.
Treatment
Currently, Ganciclovir is the drug of choice for CMV disease. Other approved drugs include Cidofovir and Foscarnet. These drugs are used judiciously and handled as a cytotoxic drug in the clinical setting. None of the currently approved drugs for CMV have proven to be well tolerated. Ganciclovir is commonly associated with a range of serious hematological adverse effects. It is also considered a potential human carcinogen.
CMV Market
In 2008, the market for CMV drugs was $600 million with Ganciclovir controlling over 90% of the market. Leading industry observers estimate that sales for CMV disease would top one billion dollars in sales if there were a drug available that was both safe and effective. Many patients currently taking drugs approved for CMV disease will require a kidney transplant due to the serious toxicities associated with these drugs.
About NIAID
NIAID is a component of the National Institutes of Health (NIH) our Nation's Medical Research Agency. NIH is the primary federal agency for conducting and supporting basic clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. NIAID supports basic and applied research to prevent, diagnose, and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria, and illness from potential agents of bioterrorism.
About Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. (formerly Alfacell Corporation) is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE®, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer, viruses, and other life-threatening diseases. For more information, visit www.tamirbio.com.
Safe Harbor: This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.
| CONTACT: | Tamir Biotechnology, Inc. | |
| Charles Muniz, President, CEO and CFO | ||
| 732-823-1003 X 203 | ||
SOURCE Tamir Biotechnology, Inc.
Saturday, August 22, 2009
About CMV
Cytomegalovirus, or CMV, is found universally throughout all geographic locations and socioeconomic groups, and has infected between 50% and 85% of adults in the United States by 40 years of age. CMV is also the virus most frequently transmitted to a developing child before birth.
Each year in the United States approximately 30,000 children are born with congenital CMV causing an estimated 400 deaths and leaving approximately 8,000 children with permanent disabilities such as hearing or vision loss, or mental retardation. It is estimated that 1 in every 150 children are born infected with congenital CMV. More children are adversely affected by congenital CMV than by several better-known childhood diseases or syndromes such as Down Syndrome, Fetal Alcohol Syndrome and neural tube defects.
High-risk Groups
CMV infection is important to certain high-risk groups, especially pregnant women. Major areas of concern are the risk of infection to the unborn baby during pregnancy and the risk of infection to pregnant women who work with children, including mothers who have already had children.
Approximately 40-50% of college-educated, white women of childbearing age in this country currently have no protective immunity to CMV, making this group most vulnerable to contracting a primary CMV infection while pregnant and passing the disease on to an unborn baby. Young, American women of the middle and upper socio-economic classes have lower rates of natural CMV immunity because many have had minimal contact with small children prior to becoming pregnant themselves.
Transmission
CMV can be transmitted to the unborn child of a mother with a primary or a recurrent CMV infection. When a baby catches CMV prior to birth it is known as a congenital CMV infection. Approximately 90% of all infants who are infected with CMV prior to delivery are born without symptoms of the virus; however, the remaining 10% will have varying degrees of abnormalities.
Transmission of the virus is often preventable because it is most often transmitted through infected bodily fluids that come in contact with hands and then are absorbed through the nose or mouth of a susceptible person. Therefore, care should be taken when handling infants, small children and items like diapers. Simple hand washing with soap and water is effective in removing the virus from the hands.
Effects on Pregnancy
The incidence of primary (or first) CMV infection in pregnant women in the United States varies from 1% to 3%. When infected with CMV, most women have no symptoms and very few have symptoms resembling mononucleosis. It is their developing unborn babies that may be at risk for congenital CMV disease. CMV remains the most common cause of congenital (meaning from birth) viral infection in the United States. For infants who are infected by their mothers during pregnancy, two potential problems exist:
- Generalized infection may occur in the infant, and symptoms may range from moderate enlargement of the liver and spleen (with jaundice) to fatal illness. With supportive treatment, most infants with CMV disease usually survive. However, 80% to 90% will have complications within the first few years of life that may include hearing loss, vision impairment, and varying degrees of mental retardation.
- Another 5% to 10% of infants who are infected but without symptoms at birth will subsequently have varying degrees of hearing and mental or coordination problems.